Cypherpunk Technologies (CYPH) Expected to Announce Earnings on Wednesday

Cypherpunk Technologies (NASDAQ:CYPH) will likely be issuing its results before the market opens on Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

Cypherpunk Technologies Price Performance

NASDAQ CYPH opened at $0.70 on Monday. The company has a fifty day moving average of $0.74 and a two-hundred day moving average of $0.87. The company has a market capitalization of $62.62 million, a PE ratio of 9.94 and a beta of -0.15. Cypherpunk Technologies has a 1 year low of $0.22 and a 1 year high of $3.70.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CYPH. Millennium Management LLC acquired a new stake in shares of Cypherpunk Technologies during the fourth quarter worth about $37,000. LPL Financial LLC acquired a new position in Cypherpunk Technologies in the 4th quarter valued at about $38,000. HighTower Advisors LLC acquired a new position in Cypherpunk Technologies in the 4th quarter valued at about $59,000. State Street Corp purchased a new stake in Cypherpunk Technologies during the 4th quarter valued at approximately $163,000. Finally, Acadian Asset Management LLC raised its stake in Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after acquiring an additional 1,056,047 shares during the last quarter. 30.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CYPH has been the subject of several research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Cypherpunk Technologies in a report on Thursday, January 22nd. Wall Street Zen upgraded Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, November 25th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cypherpunk Technologies presently has a consensus rating of “Reduce”.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.